The addition of Tecentriq (atezolizumab) to both induction therapy and maintenance therapy for patients with ES-SCLC has improved median progression free survival (PFS) and overall survival. However, ...

The Roanoke Chapter of the Southern Christian Leadership Conference is commemorating the March 7, 1965, March for Voting Rights at 4 p.m. Friday at the Martin Luther King Jr. Plaza on Henry Street ...

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft ...

Background: SCLC is an aggressive neuroendocrine tumor, with initial sensitivity to chemotherapy and radiotherapy often followed by chemoresistant disease progression. Notch signaling is a key ...

A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC). Background: To compare the presenting and prognostic characteristics, cause-specific survival (CSS) rates, and ...

The latest setback is in a phase 3 trial of MSD's anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab in small cell lung cancer (SCLC), with a lack of efficacy and side effects both ...

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Michaela was born and raised in Walpole, Massachusetts, where her love for journalism first started. She attended Walpole High School and anchored their morning news sharing the daily announcements ...

An illustration of a magnifying glass. An illustration of a magnifying glass.